Viking Therapeutics Inc (VKTX)
79.61
+0.02
(+0.03%)
USD |
NASDAQ |
May 08, 15:32
Viking Therapeutics Enterprise Value: 7.813B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 07, 2024 | 7.813B |
May 06, 2024 | 7.661B |
May 03, 2024 | 7.524B |
May 02, 2024 | 7.391B |
May 01, 2024 | 7.465B |
April 30, 2024 | 7.812B |
April 29, 2024 | 7.353B |
April 26, 2024 | 7.231B |
April 25, 2024 | 6.630B |
April 24, 2024 | 6.212B |
April 23, 2024 | 6.197B |
April 22, 2024 | 6.078B |
April 19, 2024 | 6.030B |
April 18, 2024 | 6.168B |
April 17, 2024 | 6.367B |
April 16, 2024 | 6.530B |
April 15, 2024 | 6.419B |
April 12, 2024 | 6.601B |
April 11, 2024 | 6.849B |
April 10, 2024 | 6.935B |
April 09, 2024 | 7.065B |
April 08, 2024 | 7.401B |
April 05, 2024 | 7.464B |
April 04, 2024 | 7.159B |
April 03, 2024 | 7.683B |
Date | Value |
---|---|
April 02, 2024 | 7.563B |
April 01, 2024 | 7.800B |
March 28, 2024 | 8.676B |
March 27, 2024 | 8.811B |
March 26, 2024 | 8.535B |
March 25, 2024 | 7.254B |
March 22, 2024 | 7.293B |
March 21, 2024 | 7.408B |
March 20, 2024 | 7.457B |
March 19, 2024 | 6.812B |
March 18, 2024 | 6.611B |
March 15, 2024 | 6.524B |
March 14, 2024 | 6.752B |
March 13, 2024 | 7.507B |
March 12, 2024 | 6.976B |
March 11, 2024 | 6.575B |
March 08, 2024 | 7.488B |
March 07, 2024 | 7.730B |
March 06, 2024 | 9.609B |
March 05, 2024 | 9.250B |
March 04, 2024 | 9.627B |
March 01, 2024 | 8.323B |
February 29, 2024 | 7.490B |
February 28, 2024 | 9.269B |
February 27, 2024 | 8.306B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-25.30M
Minimum
Mar 16 2020
9.627B
Maximum
Mar 04 2024
726.71M
Average
241.54M
Median
Oct 26 2021
Enterprise Value Benchmarks
Eli Lilly and Co | 762.91B |
Pfizer Inc | 215.68B |
Madrigal Pharmaceuticals Inc | 3.817B |
Akero Therapeutics Inc | 993.87M |
Terns Pharmaceuticals Inc | 108.63M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -27.36M |
Total Expenses (Quarterly) | 34.07M |
EPS Diluted (Quarterly) | -0.26 |
Earnings Yield | -1.17% |